Studies since the start of the pandemic have noted that pigs exposed to the coronavirus don’t show clinical signs of disease nor do they transmit the virus to other animals. Iowa State University scientists have uncovered important clues that shed light on why pigs don’t get sick, and the discovery could lead to better treatments for COVID-19 in humans.
A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy ― and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells ― may mount an inadequate immune response to COVID-19 vaccination. The findings are published in Mayo Clinic Proceedings.
La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.
A new study from Washington University School of Medicine in St. Louis shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma. The study in mice suggests promise for a phase 1/2 clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine that is investigating a long-acting type of IL-7 in patients with glioblastoma.
Researchers studying how small worms defend themselves against pathogens have discovered a gene that acts as a first-line response against infection. They identified “ZIP-1” as a centralized hub for immune response, a finding could have implications for understanding human immunity against viruses.
A new study published Jan. 13 in Science reports that Epstein-Barr virus infection – known for causing mononucleosis or “mono,” could be a primary cause for multiple sclerosis.
The human immune system, that marvel of complexity, subtlety, and sophistication, includes a billion-year-old family of proteins used by bacteria to defend themselves against viruses, scientists at Dana-Farber Cancer Institute and in Israel have discovered.
An artery is not like a nose. Or is it?
Scientists at La Jolla Institute for Immunology (LJI) have discovered that immune cells in arteries can "sniff" out their surroundings and cause inflammation.
A new, targeted therapy, developed by researchers from the Azrieli Faculty of Medicine of Bar-Ilan University, the Albert Einstein College of Medicine, the University of Houston, and the pharmaceutical company Equillium, together with several other academic collaborators, inhibits specific immune cells associated with lupus nephritis, and was effective in improving kidney inflammation in animal models of lupus and lupus nephritis. The new approach could serve as an alternative to current treatments targeting multiple immune cells, and provide a more effective and potentially personalized remedy for lupus nephritis. The development was recently reported in the Journal of Clinical Investigation.
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures. However, little is known about how tertiary lymphoid structures form. In a new article published in Immunity, Moffitt Cancer Center researchers report on the molecular and cellular mechanisms that control tertiary lymphoid structure formation within tumors.
Researchers at Penn Medicine have discovered a new, more effective method of preventing the body’s own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy’s effectiveness.
There is growing evidence that the currently available MRNA vaccines provide some protection against the Omicron variant (B.1.1.529) of the SARS-COV-2 virus, the coronavirus that causes COVID-19. According to the CDC, preliminary results for Omicron from South Africa showed that the Pfizer vaccine provided 70% protection against COVID-19 hospitalization and 33% against infection, during the current Omicron wave. Granted, the protection is reduced compared with the Delta variant (93% for hospitalization and 80% for infection).
An experimental immunotherapy can temporarily reprogram patients’ immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.
Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system respond to SARS-CoV-2, the virus that causes COVID-19.
مدينة روتشستر، ولاية مينيسوتا - تُظهر أبحاث مايو كلينك أن إضافة علاج الحمض النووي الريبوزي المرسال (mRNA) يحسن الاستجابة للعلاج المناعي للسرطان لدى المرضى الذين لم يستجيبوا للعلاج. ويستخدم العلاج المناعي جهاز المناعة في الجسم للوقاية من السرطان ومكافحته والقضاء عليه. كما نُشرت الدراسة في أبحاث مناعة السرطان، إحدى مجلات الجمعية الأمريكية لأبحاث السرطان.
a adição da terapia com RNA mensageiro ou mRNA, melhora a reposta da imunoterapia ao câncer nos pacientes que não estavam respondendo ao tratamento, demonstra uma pesquisa da Mayo Clinic. A imunoterapia utiliza o sistema imunológico para prevenir, controlar e eliminar o câncer. O estudo está publicado no Cancer Immunology Research, uma revista médica da Associação Americana para Pesquisa do Câncer.
Añadir la terapia con ARN mensajero mejora la respuesta a la inmunoterapia contra el cáncer en los pacientes que no respondieron al tratamiento, revela un estudio de Mayo Clinic. La inmunoterapia utiliza al sistema inmunitario para prevenir, controlar y eliminar el cáncer. El estudio se publicó en Cancer Immunology Research (Investigación Inmunológica sobre el Cáncer), revista de la Asociación Americana de Investigación sobre el Cáncer.
A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for adults with a form of myasthenia gravis. This rare and chronic autoimmune disease is characterized by debilitating and potentially life-threatening muscle weakness.
Scientists at the La Jolla Institute for Immunology (LJI) have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.
MED-CU has invented a Personalized Probiotics (Dispensing) Machine to deliver live microorganisms that have health benefits to treat patients with unclear health problems and those with microbial imbalances or “dysbiosis”.
The virus that causes COVID-19 has adopted some stealth moves to stay alive and kicking, and one secret to its success is hiding from the immune system by spreading through cell-to-cell transmission, a new study has found.
What if the key to aging well lies in reprogramming immune system cells to strengthen them against infections and cancer? Researchers at UT Southwestern are working to find out.
A new study from COVID researchers at Columbia and the University of Hong Kong adds more evidence that the omicron variant can evade the immune protection conferred by vaccines and natural infection.
Eight days of intense meditation cause robust activation of the immune system, University of Florida researchers and their colleagues have found. The findings are believed to be the first comprehensive genomic study of how meditation affects the biological processes directly involved in disease development.
os especialistas da Mayo Clinic afirmam que, independentemente da variante, a prevenção da infecção funciona. As vacinas reduzem e previnem a hospitalização e morte de acordo com o conhecimento atual.
مدينة روتشستر، ولاية مينيسوتا- يقول خبراء مايو كلينك، بغض النظر عن المتحور، فإن الوقاية من العدوى تجدي نفعًا. وتقلل اللقاحات من دخول المستشفى والوفاة وتقي منهما بناءً على المعرفة الحالية. إذا كنتَ قادرًا على التطعيم أو مؤهلًا للحصول على جرعة معززة، فقم بذلك الآن.
Los expertos de Mayo Clinic dicen que, independientemente de la variante, la prevención de la infección funciona. Las vacunas reducen y previenen los casos de hospitalización y muerte, según lo que se sabe hasta ahora. Si reúnes las condiciones para vacunarte o recibir un refuerzo, hazlo ahora.
Adding messenger RNA, or mRNA therapy improves the response to cancer immunotherapy in patients who weren't responding to the treatment, Mayo Clinic research shows. Immunotherapy uses the body’s immune system to prevent, control and eliminate cancer. The study is published in Cancer Immunology Research, a journal of the American Association for Cancer Research.
A long, long time ago, the BCG vaccine was approved for use against tuberculosis (TB), and it's still given to infants today. For generations, the vaccine has saved lives and prevented untold suffering.
Are you worried about the status of your immune system? You're not alone. People all over the globe have been feeling anxious about their health and the health of their loved ones.
Asthma has been associated with a lowered risk of brain tumors, and researchers at Washington University School of Medicine in St. Louis now think they know why: Immune cells activated under conditions of asthma are less able to promote the growth of brain tumors. The findings could lead to new therapeutic approaches.
Mayo Clinic experts say, regardless of the variant, prevention of infection works. The vaccines reduce and prevent hospitalization and death based on current knowledge. If a person can get vaccinated or is eligible for a booster, do it now.
But what about these variants? Why do they show up, and how? Here is what Mayo Clinic experts are saying:
The combination of two monoclonal antibodies, called Evusheld, was authorized as a pre-exposure prophylaxis to prevent COVID-19 in adults and children 12 years and older who have compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine.
Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.
Two complementary studies show that defibrotide can successfully suppress the formation and progression of neutrophil extracellular traps, or NETs, which are web-like networks of toxic proteins that play a role in forming blood clots and promoting inflammation in several disease, including COVID-19. Researchers say findings may set the stage for defibrotide clinical trials in potentially several diseases.
A combination of vaccination and naturally acquired infection appears to boost the production of maximally potent antibodies against the COVID-19 virus, new UCLA research finds.
The study, called COVID CommUNITY- First Nations, will collect, analyze, and report data relating to COVID-19 vaccine effectiveness and safety, as well as explore hesitancy in three First Nations communities in Canada: Six Nations of the Grand River in southwestern Ontario; Lac La Ronge Indian Band in Saskatchewan; and Wendake in Quebec.
Biomedical scientists at LMU have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.
Among HIV-positive black and Latino men who have sex with men, the use of methamphetamine combined with intimate partner violence may increase the risk for developing chronic diseases such as cardiovascular disease and other disorders.
Scientists at the Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotechnology, located at Temple University’s College of Science and Technology, working with collaborators in Italy, have described the age-related differences in inflammatory response to an emerging immunotherapy treatment for Non-Small-Cell Lung Cancer (NSCLC) called PD-1 blockade.
Scientists at La Jolla Institute for Immunology (LJI) and Massachusetts Institute of Technology (MIT), have found a possible way to improve the effectiveness of COVID-19 vaccines—and any vaccine.